-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

Benzinga·11/05/2026 19:13:39
Listen to the news
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $35 to $32.